5/9/2025

Janusmed sex and gender

Janusmed sex and gender – Ibrutinib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C C
C C

Ibrutinib

Ibrutinib

Class : C

Show all info

Print

Contact us

  1. Regionala cancercentrum i samverkan. Nationellt vårdprogram kronisk lymfatisk leukemi. Kunskapsbanken [www]. [updated 2024-01-23, cited 2024-09-13].

  2. Imbruvica (ibrutinib). Summary of Product Characteristics. European Medicines Agency [updated 2019-06-25, cited 2024-08-23]

  3. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-23.

  4. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031-2042.

  5. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409-1418.

  6. Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):535-552.

  7. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16.

  8. Rhodes JM, LoRe VA, Mato AR, Chong EA, Barrientos JC, Gerson JN et al. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. Clin Lymphoma Myeloma Leuk. 2020;20(7):438-444e1.

  9. Food and Drug Administration (FDA). Drug label - Imbruvica (ibrutinib). Drugs@FDA [www]. [updated 2024-05-01, cited 2024-09-02].

  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]

  1. Regionala cancercentrum i samverkan. Nationellt vårdprogram kronisk lymfatisk leukemi. Kunskapsbanken [www]. [updated 2024-01-23, cited 2024-09-13].
  2. Imbruvica (ibrutinib). Summary of Product Characteristics. European Medicines Agency [updated 2019-06-25, cited 2024-08-23]
  3. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-23.
  4. Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood. 2019;133(19):2031-2042.
  5. O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409-1418.
  6. Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):535-552.
  7. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16.
  8. Rhodes JM, LoRe VA, Mato AR, Chong EA, Barrientos JC, Gerson JN et al. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. Clin Lymphoma Myeloma Leuk. 2020;20(7):438-444e1.
  9. Food and Drug Administration (FDA). Drug label - Imbruvica (ibrutinib). Drugs@FDA [www]. [updated 2024-05-01, cited 2024-09-02].
  10. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2023 [cited 2024-03-06.]